Hematology/Oncology

Top Story

CT/MRI LI-RADS update meets AASLD liver cancer guidance

August 20, 2018
In the Journals Plus

Insurance status may impact follicular lymphoma survival

August 20, 2018
Patients with follicular lymphoma who had private insurance demonstrated better survival outcomes than those with Medicare, Medicaid or no insurance, according to…

Lion TCR T-cell therapy for liver cancer to undergo phase 1/2 trial

August 20, 2018
Lion TCR received approval from the Health Sciences Authority in Singapore to perform a phase 1/2 multicenter clinical study of its LioCyx candidate for treating liver…
FDA News

FDA grants regular approval to Keytruda-chemotherapy combination for nonsquamous non-small cell lung cancer

August 20, 2018
The FDA granted regular approval to pembrolizumab in combination with pemetrexed and platinum-based chemotherapy as first-line treatment of patients with metastatic…
FDA News

FDA grants fast track designation to AVB-S6-500 for ovarian cancer

August 20, 2018
The FDA granted AVB-S6-500 — an inhibitor of the GAS6-AXL signaling pathway — fast track designation for the treatment of women with
More Headlines »
CME CNE CPE

Immune Checkpoint Inhibitors for Genitourinary Cancers: Practice Essential for Community Oncologists and Advanced Practice Providers

This activity is supported by an educational grant from Merck & Co., Inc.

For many years, the mainstay of initial treatment for metastatic bladder cancer has been chemotherapy. However…
More »
Video
Meeting News

VIDEO: Physician leadership development ‘now more than ever’ imperative

August 17, 2018
More »
Resource Centers
Immuno-Oncology Resource Center

Immuno-Oncology Resource Center

CME CPE CNE

Decisions, Decisions: Differentiating Checkpoint Inhibitors for Bladder Cancer

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Lung cancer is a leading cause of cancer death worldwide. The American Cancer Society estimates that there will be…
More »
Current Issues
View the Current Issue
HemOnc Today